Is genotype 3 of the hepatitis C virus the new villain? (Q38155123)

29 August 2017

Is genotype 3 of the hepatitis C virus the new villain? (English)

1 reference

29 August 2017

1 reference

1 reference

Nicolas Goossens

1

1 reference

PubMed ID

24155107

29 August 2017

Francesco Negro

series ordinal

2

1 reference

PubMed ID

24155107

29 August 2017

language of work or name

English

0 references

publication date

14 April 2014

1 reference

29 August 2017

1 reference

29 August 2017

59

1 reference

29 August 2017

6

1 reference

29 August 2017

2403-2412

1 reference

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

29 August 2017

1 reference

Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study

21 January 2018

1 reference

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

The global health burden of hepatitis C virus infection

21 January 2018

1 reference

The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study

21 January 2018

1 reference

Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients

21 January 2018

1 reference

The interaction of metabolic factors with HCV infection: does it matter?

21 January 2018

1 reference

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

21 January 2018

1 reference

Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C

21 January 2018

1 reference

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress

21 January 2018

1 reference

Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly

21 January 2018

1 reference

Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection

21 January 2018

1 reference

Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver

21 January 2018

1 reference

Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.

21 January 2018

1 reference

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

21 January 2018

1 reference

Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a

21 January 2018

1 reference

Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up

21 January 2018

1 reference

Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis

21 January 2018

1 reference

Autophagy protects cells from HCV-induced defects in lipid metabolism

21 January 2018

1 reference

Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets.

21 January 2018

1 reference

PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism.

21 January 2018

1 reference

Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections

21 January 2018

1 reference

Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors

21 January 2018

1 reference

IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes

21 January 2018

1 reference

Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis

21 January 2018

1 reference

Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection

21 January 2018

1 reference

Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France

21 January 2018

1 reference

Epidemiology of viral hepatitis and hepatocellular carcinoma

21 January 2018

1 reference

Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis

21 January 2018

1 reference

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

21 January 2018

1 reference

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

Non-genomic loss of PTEN function in cancer: not in my genes.

21 January 2018

1 reference

Impact of PTEN expression on the outcome of hepatitis C virus-positive cirrhotic hepatocellular carcinoma patients: possible relationship with COX II and inducible nitric oxide synthase

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis

21 January 2018

1 reference

Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future

21 January 2018

1 reference

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

21 January 2018

1 reference

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

21 January 2018

1 reference

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.

21 January 2018

1 reference

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.

21 January 2018

1 reference

PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

21 January 2018

1 reference

Role of seipin in lipid droplet morphology and hepatitis C virus life cycle

21 January 2018

1 reference

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

Histologic observations in human hepatitis non-A, non-B

21 January 2018

1 reference

7 January 2021

Investigation of the role of SREBP-1c in the pathogenesis of HCV-related steatosis

1 reference

7 January 2021

Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis

1 reference

7 January 2021

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.26905

1 reference

29 August 2017

1 reference

PubMed ID

24155107